Literature DB >> 18671909

Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke.

Simona Farina1, Claudia Migliorini, Marialuisa Gandolfi, L Bertolasi, Matteo Casarotto, Paolo Manganotti, Antonio Fiaschi, Nicola Smania.   

Abstract

Optimal treatment of spasticity requires a combination of pharmacotherapy and muscle lengthening. We evaluated 13 stroke patients with equinovarus foot randomized to treatment with either botulinum toxin A (BTA) injection plus ankle-foot casting (n=6) or BTA alone (n=7). The tibialis posterior and calf muscles (range of BTA injection: 190 to 320 U) were treated in each patient. Castings were worn at night for four months. Each patient was examined before, and at two and four months after BTA injection using the static and dynamic baropodometric tests, the Modified Ashworth Scale and the 10-meter walking test. At two months, therapeutic effects were observed in both groups. At four months, the study group showed further clinical improvement, while the control group returned to baseline performance. Thus, prolonged stretching of spastic muscles after BTA injection affords long-lasting therapeutic benefit, enhancing the effects of the toxin alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671909

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  15 in total

1.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 2.  [Efficacy of early neurological and neurosurgical rehabilitation : Evidence-based treatment, outcome and prognostic factors].

Authors:  M Pohl; M Bertram
Journal:  Nervenarzt       Date:  2016-10       Impact factor: 1.214

3.  Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.

Authors:  Nicola Smania; Carlo Colosimo; Anna Rita Bentivoglio; Giorgio Sandrini; Alessandro Picelli
Journal:  Funct Neurol       Date:  2013 Oct-Dec

4.  The Use of Botulinum Toxin for Treatment of Spasticity.

Authors:  Sheng Li; Gerard E Francisco
Journal:  Handb Exp Pharmacol       Date:  2021

Review 5.  Stretch for the treatment and prevention of contractures.

Authors:  Lisa A Harvey; Owen M Katalinic; Robert D Herbert; Anne M Moseley; Natasha A Lannin; Karl Schurr
Journal:  Cochrane Database Syst Rev       Date:  2017-01-09

6.  Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial.

Authors:  Ryuji Kaji; Yuka Osako; Kazuaki Suyama; Toshio Maeda; Yasuyuki Uechi; Masaru Iwasaki
Journal:  J Neurol       Date:  2010-04-01       Impact factor: 4.849

Review 7.  OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review.

Authors:  Luba Nalysnyk; Spyridon Papapetropoulos; Philip Rotella; Jason C Simeone; Katharine E Alter; Alberto Esquenazi
Journal:  BMC Neurol       Date:  2013-09-08       Impact factor: 2.474

8.  Botulinum toxin type-A in the management of spastic equinovarus deformity after stroke. Comparison of 2 injection techniques.

Authors:  Ali H Otom; Imad M Al-Khawaja; Khalid W Al-Quliti
Journal:  Neurosciences (Riyadh)       Date:  2014-07       Impact factor: 0.906

9.  Evaluation of clinical outcomes of patients with post-stroke wrist and finger spasticity after ultrasonography-guided BTX-A injection and rehabilitation training.

Authors:  Li Jiang; Zu-Lin Dou; Qing Wang; Qiao-Yuan Wang; Meng Dai; Zhen Wang; Xiao-Mei Wei; Ying-Bei Chen
Journal:  Front Hum Neurosci       Date:  2015-09-02       Impact factor: 3.169

10.  Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.

Authors:  Ja Young Choi; Soojin Jung; Dong Wook Rha; Eun Sook Park
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.